Search results for "VISCERAL ADIPOSITY"

showing 10 items of 21 documents

Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index

2015

The aim of the study is to clarify the relationship between adipose tissue dysfunction, metabolic profile and growth hormone (GH)/insulin-like growth factor (IGF)-I secretion in healthy adult subjects. We investigated the metabolic profile in a cohort of 231 consecutive healthy subjects in relation to GH, IGF-I levels, and visceral adiposity index (VAI). Anthropometric measures, lipid profile, and glucose and insulin levels during oral glucose tolerance test, Homa-IR and ISI Matsuda, IGF-I and GH peak after GHRH plus Arginine test were analyzed. The subjects with high VAI showed lower GH peak (22.8 ± 11.1 vs. 42.2 ± 21.3 µg/L; p = 0.049) and lower IGF-I (presented as IGF-I under normal rang…

AdultMaleRiskmedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissueIntra-Abdominal FatBiologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyMetabolic DiseasesInternal medicineDiabetes mellitusmedicineHealth Status IndicatorsHumansMetabolic riskInsulin-Like Growth Factor IProspective cohort studyGrowth hormoneSubclinical infectionGH deficiencymedicine.diagnostic_testHuman Growth HormoneInsulinGH deficiency; Growth hormone; Metabolic risk; Visceral adiposity; Endocrinology; Endocrinology Diabetes and MetabolismMiddle Agedmedicine.diseaseEndocrinologyBlood pressureCohortFemaleVisceral adiposityLipid profile
researchProduct

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

2012

Context: The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunction, strongly associated with insulin sensitivity in both the general and specific populations of patients at metabolic risk. Objective: The objective of the study was to test VAI as a useful tool to assess early metabolic risk in acromegaly. Patients: Twenty-four newly diagnosed acromegalic patients (11 women and 13 men, aged 54.9 ± 13.6 yr) were grouped into those with normal (group A, n = 13, 54.2%) and those with high VAI (group B, n = 11, 45.8%). Outcome Measures: Glucose, hemoglobin A1c, nadir and area under the curve (AUC) of GH (AUCGH) during the oral glucose tolerance test, AUCCpeptide…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineContext (language use)Intra-Abdominal FatBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceAdipokinesInternal medicineAcromegalymedicineAcromegaly Visceral Adiposity IndexHumansInsulin-Like Growth Factor IAdiposityAgedAdiponectinbusiness.industryHuman Growth HormoneLeptinBiochemistry (medical)Area under the curveMiddle Agedmedicine.diseaseEndocrinologyArea Under CurveAcromegalyFemaleMetabolic syndromeInsulin ResistancebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study

2020

Abstract Purpose To evaluate factors influencing the insulin and levothyroxine requirement in patients with autoimmune polyglandular syndrome type 3 (APS-3) vs. patients with type 1 diabetes mellitus (T1DM) and autoimmune hypothyroidism (AH) alone, respectively. Methods Fifty patients with APS-3, 60 patients with T1DM and 40 patients with AH were included. Anthropometric, clinical and biochemical parameters were evaluated in all patients. Insulin requirement was calculated in patients with APS-3 and T1DM, while levothyroxine requirement was calculated in APS-3 and AH. Results Patients with APS-3 showed higher age (p = 0.001), age of onset of diabetes (p = 0.006) and TSH (p = 0.004) and lowe…

Blood GlucoseMale0301 basic medicineendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipose tissueGastroenterologySettore MED/13 - Endocrinologia0302 clinical medicineEndocrinologyAutoimmune hypothyroidism Cardiovascular risk Irisin Type 1 diabetes mellitus Visceral adiposity indexInsulinPolyendocrinopathies AutoimmuneThyroid diseaseMiddle AgedPrognosisFemaleOriginal Articlemedicine.drugAdultIrisinmedicine.medical_specialtyWaistAdolescentLevothyroxineType 1 diabetes mellitus030209 endocrinology & metabolismHashimoto DiseaseYoung Adult03 medical and health sciencesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAgedType 1 diabetesAutoimmune hypothyroidismbusiness.industryInsulinThyroiditis AutoimmuneCardiovascular riskmedicine.diseaseVisceral adiposity indexThyroxineDiabetes Mellitus Type 1030104 developmental biologyAge of onsetbusinessBiomarkersFollow-Up StudiesJournal of Endocrinological Investigation
researchProduct

Clinical indications and proper use of Visceral Adiposity Index.

2013

Index (economics)Endocrinology Diabetes and MetabolismMedicine (miscellaneous)PhysiologyIntra-Abdominal FatTriglycerides bloodBody Mass Indexchemistry.chemical_compoundBody Fat DistributionHumansMedicineTriglyceridesAdiposityBody fat distributionVisceral Adiposity IndexNutrition and DieteticsCholesterolbusiness.industryCholesterol HDLCholesterol LDLModels TheoreticalchemistryWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBody mass index
researchProduct

Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian S…

2011

Abstract Background The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity. Our aim was to find the optimal cut-off points of VAI identifying a visceral adipose dysfunction (VAD) associated with cardiometabolic risk in a Caucasian Sicilian population. Methods Medical check-up data of 1,764 Primary Care patients (PC patients) were retrospectively and cross-sectionally examined using a receiver-operating characteristic (ROC) curve to determine appropriate stratified-for-age cut-off of VAI, for t…

MaleCross-sectional studyEndocrinology Diabetes and MetabolismClinical BiochemistrySettore MED/13 - EndocrinologiaEndocrinologyReference ValuesRisk Factorscardiometabolic riskPrevalenceMyocardial infarctionSicilylcsh:RC620-627Aged 80 and overMetabolic Syndromeeducation.field_of_studyMiddle Agedlcsh:Nutritional diseases. Deficiency diseasesCardiovascular DiseasesCardiologyvisceral adipose dynsfunctionFemaleAdultmedicine.medical_specialtyWaistAdolescentPopulationVisceral adiposity index VAI Obesity cardiometabolic risk visceral adipose dynsfunctionClinical nutritionIntra-Abdominal FatWhite PeopleYoung AdultInternal medicineDiabetes mellitusmedicineHumansBody Weights and MeasuresObesitycardiovascular diseaseseducationAgedRetrospective StudiesBiochemistry medicalbusiness.industryResearchBiochemistry (medical)medicine.diseaseVAIEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2Metabolic syndromebusinessBody mass indexLipids in Health and Disease
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

The current version of the visceral adiposity index is not suitable for application in pediatric populations: comments on the article by Al-Daghri et…

2014

The current version of the visceral adiposity index is not suitable for application in pediatric populations: comments on the article by Al-Daghri et al .

MaleVisceral Adiposity IndexGerontologyIndex (economics)Anthropometrybusiness.industryeducationMEDLINEIntra-Abdominal FatPediatrics Perinatology and Child HealthHumansMedicineFemalebusinessAdiposityPediatric Research
researchProduct

Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus

2015

Objective Nonalcoholic fatty liver disease is very frequent in both type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MS), which share clinical and metabolic characteristics. Whether and to which extent these characteristics can predict the degree of liver steatosis are not entirely clear. Patients and methods We determined liver fat (divided into four classes) by standard sonographic images, and clinical and biochemical variables, in 60 consecutive patients with T2DM and with features of the MS. We examined both simple and multiple correlations between the degree of liver steatosis and the variables measured. Results Increased liver fat (defined as >5% of liver mass) was detec…

Malenonalcoholic fatty liver diseasemedicine.medical_specialtytype 2 diabetes mellitusmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateGastroenterologyleptinliver steatosispredictive modelInsulin resistanceNon-alcoholic Fatty Liver DiseaseInternal medicineinsulin resistanceNonalcoholic fatty liver diseasemedicineHumansInsulinAdiposityAgedUltrasonographyvisceral adiposityGlycated HemoglobinMetabolic SyndromeSettore SECS-S/06 - Metodi mat. dell'economia e Scienze Attuariali e FinanziarieModels StatisticalAnthropometryHepatologybusiness.industryInsulinHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity;GastroenterologyType 2 Diabetes MellitusHemoglobin A1c; insulin resistance; leptin; liver steatosis; metabolic control; multiple regression analysis; nonalcoholic fatty liver disease; predictive model; type 2 diabetes mellitus; visceral adiposity; Gastroenterology; Hepatologymetabolic controlmultiple regression analysisMiddle AgedHepatologymedicine.diseaseEndocrinologyDiabetes Mellitus Type 2Hemoglobin A1cMetabolic control analysisFemaleWaist CircumferenceSteatosisMetabolic syndromebusinesshemoglobin A1c leptin liver steatosis metabolic control multiple regression analysis nonalcoholic fatty liver disease insulin resistance predictive model type 2 diabetes mellitus visceral adiposity
researchProduct

Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease

2012

Background: Metabolic factors have been associated with liver damage in patients with non-alcoholic fatty liver disease (NAFLD). Aims To test a new marker of adipose dysfunction, the visceral adiposity index (VAI), in NAFLD patients to assess whether or not it is associated with host factors, and to investigate a potential correlation with histological findings. Methods One hundred and forty-two consecutive NAFLD patients were evaluated by liver biopsy, and clinical and metabolic measurements, including insulin resistance with the homeostasis model assessment (HOMA), and VAI by using waist circumference, body mass index, triglycerides and HDL. Serum levels of TNFα, IL-6, adiponectin and lep…

Settore MED/12 - Gastroenterologiavisceral adiposity index nafld liver fibrosis liver biopsySettore MED/08 - Anatomia PatologicaSettore MED/13 - Endocrinologia
researchProduct

THE RELATIONSHIP BETWEEN VISCERAL ADIPOSITY INDEX AND DISABILITY FUNCTION IN A COHORT OF PSORIATIC ARTHRITIS PATIENTS

2013

VISCERAL ADIPOSITY PSORIATIC ARTHRITIS
researchProduct